Eisai, Sysmex partner on dementia diagnostics initiative
Currently, Alzheimer's disease is diagnosed using various tests, such as brain imaging and examinations of cerebrospinal fluids. There are few facilities where this testing can be done; furthermore, the tests are invasive.
Sysmex specializes in clinical diagnostics and technologies used in detection of genetic, protein and cellular biomarkers in blood samples. Eisai has more than three decades of experience working in dementia drug discovery, including the development and marketing of dementia therapy Aricept.
Officials from the companies hope the partnership will produce diagnostics that can offer earlier diagnosis, more treatment options and better monitoring for dementia patients.
Development will be led by Sysmex personnel. After regulatory approval, the company will have exclusive marketing rights to any diagnostics. Eisai will be paid upon reaching development milestones, product launches and sales royalties.
Additionally, Eisai will use any new diagnostics for the discovery and development of new dementia drugs.
Organizations in this story
Eisai 100 Tice Blvd. Woodcliff Lake, NJ 07677